SavedAdd your journal

Journals / Türk Dermatoloji Dergisi / 2016 / Cilt: 10 - Sayı: 4

Current Treatment Modalities in Advanced Melanoma

İlerlemiş Melanomada Kullanılan Güncel Tedavi Yöntemleri

Bengü Nisa AKAY
Hilayda Karakök GÜNGÖR
Pages
137–144
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, results of these recently developed and approved therapies for metastatic melanoma were presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Melanoma contributes the majority of skin cancer related deaths and shows an increasing incidence in the past years.
📊
Key Findings & Data:Despite all efforts of early diagnosis, metastatic melanoma still has a poor prognosis and remains a challenge for physicians to treat.
💡
Conclusion & Impact:In this review, results of these recently developed and approved therapies for metastatic melanoma were presented.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Melanoma contributes the majority of skin cancer related deaths and shows an increasing incidence in the past years. Despite all efforts of early diagnosis, metastatic melanoma still has a poor prognosis and remains a challenge for physicians to treat. In recent years, improved knowledge of the pathophysiology and a better understanding of the role of the immune system in tumour control have led to the development and approval of several immunotherapies and targeted therapies. The introduction and Food and Drug Administration approval of immune checkpoint inhibitor antibodies and targeted therapies has dramatically improved the clinical outcomes for patients with advanced melanoma. In this review, results of these recently developed and approved therapies for metastatic melanoma were presented.

Özet

Melanom deri kanserlerine bağlı ölümlerin en önemli sebebidir ve son yıllarda insidansında giderek artış gözlenmektedir. Erken tanıya yönelik tüm çabalara rağmen, metastatik melanom halen kötü prognoza sahip bir neoplazm olup tedavi eden doktorlar için sorun olmaya devam etmektedir. Son yıllarda patofizyolojinin ve immün sistemin tümör kontrolü üzerindeki rolünün daha iyi anlaşılması hedefe yönelik tedavilerin ve çeşitli immünoterapi ajanlarının geliştirilmesine imkan vermiştir. İmmün kontrol noktası inhibitör antikorları ve hedefe yönelik tedaviler metastatik melanomlu hastalarda klinik cevabı dramatik olarak artırmıştır. Bu derlemede metastatik melanom tedavisinde yeni geliştirilen ve onaylanan tedavilerin sonuçları anlatılmıştır.

🔖

Cite This Article

AKAY, B. N., GÜNGÖR, H. K. (2022). Current Treatment Modalities in Advanced Melanoma. Türk Dermatoloji Dergisi, Cilt: 10 - Sayı: 4, 137–144. https://ajindex.com/articles/621618

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Cancer Genome Atlas N. Genomic Classification of Cutaneous Melanoma. Cell 2015;161:1681-96.
  2. Erdmann F, Lortet-Tieulent J, Schuz J, et al. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer 2013;132:385-400.
  3. Alexander A, Samlowski WE, Grossman D, et al. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol 2003;21:2179-86.
  4. Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in nonwhite populations--US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch Dermatol 2005;141:477-81.
  5. Svedman FC, Pillas D, Taylor A, et al. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. Clin Epidemiol 2016;8:109-22.
  6. Soong SJ, Ding S, Coit D, et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol 2010;17:2006-14.
  7. Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther 2010;10:1811-23.
  8. Nakamura K, Okuyama R. Immunotherapy for advanced melanoma: Current knowledge and future directions. J Dermatol Sci 2016;83:87-94.
  9. Diamantopoulos P, Gogas H. Melanoma immunotherapy dominates the field. Ann Transl Med 2016;4:269. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825-36.
  10. Millet A, Martin AR, Ronco C, et al. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. Med Res Rev 2016.
  11. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51.
  12. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30.
  13. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348:74-80. Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol 2012;23 Suppl 8:viii10-4. Haanen JB. Immunotherapy of melanoma. EJC Suppl 2013;11:97-105.
  14. Blankenstein T, Coulie PG, Gilboa E, et al. The determinants of